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esponsibility of InstAbstract The purpose of this study was to investigate the effect of isopropyl myristate (IPM), a
penetration enhancer, on the viscoelasticity and drug release of a drug-in-adhesive transdermal patch
containing blonanserin. The patches were prepared with DURO-TAKs 87-2287 as a pressure-sensitive
adhesive (PSA) containing 5% (w/w) of blonanserin and different concentrations of IPM. An in vitro
release experiment was performed and the adhesive performance of the drug-in-adhesive patches with
different concentrations of IPM was evaluated by a rolling ball tack test and a shear-adhesion test. The
glass transition temperature (Tg) and rheological parameters of the drug-in-adhesive layers were
determined to study the effect of IPM on the mechanical properties of the PSA. The results of the
in vitro release experiment showed that the release rate of blonanserin increased with an increasing
concentration of IPM. The rolling ball tack test and shear-adhesion test showed decreasing values with
increasing IPM concentration. The results were interpreted on the basis of the IPM-induced plasticization
of the PSA, as evidenced by a depression of the glass transition temperature and a decrease in the elastic
modulus. In conclusion, IPM acted as a plasticizer on DURO-TAKs 87-2287, and it increased the release
of blonanserin and affected the adhesive properties of the PSA.
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Drug-in-adhesive patch refers to a kind of transdermal system in
which the drug and other excipients are dispersed or dissolved in
the pressure-sensitive adhesive matrix1. The drug must desorb
from patches prior to percutaneous absorption, so the drug-release
process from the patches is important in the design of a
transdermal system2. Penetration enhancers are usually added to
transdermal patches to enhance drug percutaneous absorption and
they were widely investigated for their effects on skin, such as
interfering with the lipids or proteins in skin to reduce the barrier
resistance of skin3. However, the drug-release process from
patches can also be altered by the presence of penetration
enhancers, and Song et al.4 proved it by investigating the role of
penetration enhancers on bisoprolol tartrate release from patches.
On the other hand, penetration enhancers in transdermal patches
may change the physical and mechanical properties of pressure-
sensitive adhesive (PSA)5. PSA is a kind of adhesive polymer that
can stick to a substrate by application of light pressure6. The
adhesive properties of patches are characterized by adhesion
performance tests, such as tack and shear-adhesion. The adhesion
performance of patches is strongly dependent on the viscoelastic
properties of the adhesive7. Several reports have focused on
rheological studies to characterize the viscoelastic properties of
PSA, and the effect of drug and penetration enhancers on the
viscoelastic properties of PSAs has been studied8–11. As the
viscoelastic nature of PSA controls the adhesion performance
and affects the drug-release properties of transdermal patches,
changes in the performance of patches can be attributed to a
change in viscoelastic nature of PSA.
Isopropyl myristate (IPM) is a commonly used penetration
enhancer in topical and transdermal formulations12. IPM is known
to be safe and has been used in transdermal patches to increase the
skin permeation of a large number of drugs, including amlodi-
pine13, ﬂurbiprofen14 and azasetron15. Its action on skin has been
reported, such as integration of drug into the lipid bilayer and
promotion of drug solubility in skin16,17. Several studies have
shown that IPM can affect the adhesive properties of PSA. The
incorporation of IPM into a silicon-based PSA increased the
ﬂowability and reduced the cohesion strength of the matrix18.
When IPM was added into an Eudragit E ﬁlm a decrease in the
peel adhesion strength was reported19. However, there is lack of
study on IPM's role on the drug release process from patches and
the mechanism by which IPM inﬂuences the adhesive properties of
patches is not clear.
Drug release is an important process in the transdermal patch
delivery of a drug through the skin, and the adhesive properties of
the patch are critical to the safety, efﬁcacy, and quality of
transdermal delivery products20. In this study, the effect of IPM
on blonanserin release and adhesion performance of the drug-in-
adhesive patch was investigated. To better understand the inﬂu-
ence of IPM on these performances, changes in the mechanical
properties of the drug-in-adhesive layers were characterized by
glass transition temperature (Tg) and rheological parameters.2. Materials and methods
2.1. Materials
Pressure-sensitive adhesive DURO-TAKs 87-2287 was obtained
from Henkel Corp. (New Jersey, USA). IPM was obtained fromChina National Medicines Co., Ltd. (Shanghai, China). Blonan-
serin was purchased from Linyi Shengxin Medicine Science &
Technology Co., Ltd. (Linyi, China). All other reagents used were
of analytical grade.
2.2. Preparation of adhesive layers and patches
IPM, blonanserin and DURO-TAKs 87-2287 were weighed and
dissolved in ethyl acetate and agitated thoroughly with a mechan-
ical stirrer to obtain a homogeneous solution. After evaporation of
the ethyl acetate the mixture was used for the DSC test.
Adhesive layers were prepared by coating the above-mentioned
solution onto a release liner using a wet ﬁlm applicator (SLT200,
Kaikai Co., Ltd., Shanghai, China). The adhesive layers were dried
at room temperature for 10 min and oven-dried for 15 min. After
removal of the release liner the adhesive layers with thickness of
500710 μm were used for rheological tests.
The patches were prepared by ﬁrst obtaining the adhesive
layers. They were then laminated with a polyester baking ﬁlm
(ScotchPaks 9733, 3M, USA). The concentration of blonanserin
was 5% (w/w) based on dry adhesive weight. The concentrations
of IPM were set at 0, 4%, 8%, 12% (w/w) based on the dry
adhesive. The thickness of the patches was 80710 μm and they
were used for the experiments of drug release and adhesion
performance tests.
2.3. Drug release experiment
Drug release studies were performed (n¼3; error bars represent
standard deviation) with freshly prepared patches in static Franz
cells with a receptor volume of 4.0 mL and a diffusion area of
1.7 cm2. The receptor compartment contained 0.1% (v/v) aqueous
acetic acid solution to maintain a sink condition at 32 1C and was
stirred at 600 rpm with a magnetic stirrer. Circular patches with a
diameter of 1.2 cm were attached to circular pieces of
Cellophanes membrane with a diameter of 1.6 cm. The mem-
branes with the attached patches were mounted between the donor
and the receptor compartment of Franz cells. Two-mL samples
were taken at 1, 2, 3, 4, 6, 8, 10 and 12 h and analyzed for drug
content. After each sampling the Franz cells were reﬁlled with
2 mL fresh medium.
The determination of blonanserin was performed by HPLC
equipped with a Hitachi instrument (Pump L-7100, UV–vis Detector
L-7420, T2000L work station) and Diamonsil C18 reversed-phase
column (200 mm 4.6 mm i.d., 5 μm; Dikma Technologies, Beij-
ing, China). The mobile phase was a mixture of methanol and
distilled water (with 0.5% triethylamine) at a ratio of 70:30 (v/v),
and the pH was adjusted to 3.5 with phosphoric acid. Aliquots of
20 μL from each sample were injected and eluted at a ﬂow rate of
1.0 mL/min. Measurements were taken at a wavelength of 247 nm
and the column temperature was maintained at 40 1C.
2.4. Adhesion performance
2.4.1. Rolling ball tack test
The tack of the adhesive was measured by the rolling ball tack test
using a CZY-G primary adhesive tester (Languang M&E Tech
Development Center, Jinan, China). A patch with a width of
40 mm and a length of 50 mm was positioned with the adhesive
side up on the working surface. A 10.3 mm steel ball was released
from the top of the inclined plate (angle 22.51). The distance was
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with the adhesive to the position where the ball was stopped. The
measurements were performed in triplicate.2.4.2. Shear-adhesion test
The shear-adhesion test was carried out using a CZY-S lasting
adhesive tester (Languang M&E Tech Development Center, Jinan,
China). The patch was applied to a stainless-steel test panel that
was mounted vertically and subjected to a shearing force by a
means of a given weight (1000×g) suspended from the patch. The
time taken for the patch sample to detach from the test panel was
recorded as the value of the shear strength.2.5. Differential scanning calorimetry (DSC)
Tg of the adhesives was measured by Mettler Toledo DSC-1 from
80 to 10 1C at an increasing rate of 5 1C/min. The above-
mentioned adhesive solutions were separately packed in an
aluminum pan and oven-dried to remove the solvent. The ﬁrst
cycle data were discarded and only the second cycle data were
used for determination. The Tg values were determined as the
midpoint of the inﬂection in the DSC thermograms.2.6. Rheological tests
The rheological measurements were performed on an AR 2000ex
rheometer (TA Instrument Ltd., USA) equipped with an 8 mmTable 1 Release of blonanserin, Tg of the adhesive, rolling ball tack
myristate (IPM) in the patches.
IPM content (%, w/w) Drug release Tg (1C) Rolling bal
k r
0 18.570.6 0.997 54.10 14.970.9
4 21.671.6* 0.996 60.64 13.570.7
8 27.871.5* 0.993 64.16 10.571.2*
12 28.270.7* 0.978 65.25 7.770.4*
*Statistically signiﬁcant difference (Po0.05) from the patch without IPM
Figure 1 Blonanserin release proﬁle from DuroTaks 87-2287 with
different concentrations of isopropyl myristate (IPM) versus t1/2.diameter ﬂat-plate. A gap of 500 μm was used. All tests were
performed at 3270.1 1C.
The linear viscoelastic region (LVR) of the sample was
determined by strain sweeps from 0.1% to 100% strain at constant
frequency (1 Hz). At LVR the material behaves as an elastic solid.
Frequency sweeps were conducted after determination of the LVR
by strain sweeps.
Frequency sweeps were performed from ω¼0.1 to 100 rad/s at
a strain of 1% within the LVR. G0, G″, and tan δ were determined
in dependence of the angular frequency (ω).3. Results and discussion
The blonanserin release proﬁles with different concentrations of
IPM were determined, and blonanserin release behavior ﬁtted well
with the Higuchi model. The percent of blonanserin released (%)
was plotted against t1/2 (see Fig. 1). The kinetic constant (k) which
is related to drug release rate and the correlation coefﬁcient (r)
ﬁtted by Higuchi equation are listed in Table 1. It can be seen that
the drug release rate of blonanserin from the patch increased with
increasing IPM concentration. The increase of blonanserin release
could be attributed to changes in the mechanical properties of the
adhesive after the incorporation of IPM.
To further explore the action of IPM in facilitating the drug-
release process, changes in the mechanical properties of the drug-
in-adhesive layers were investigated by a DSC test and a
rheological test.
The data obtained from DSC measurements (Table 1 and Fig. 2)
demonstrated that the Tg of DuroTak
s 87-2287 containing blonan-
serin decreased with increasing content of IPM. The Tg is a speciﬁc
measurement of the chain mobility of polymer21, so IPM caused an
increase in chain mobility of the PSA and acted as a plasticizer. The
increase in chain mobility could result in a higher formation
frequency of free volume in the PSA4. According to the free
volume theory, the free volume of the polymer facilitates drug
diffusion in a polymer2. Therefore, IPM could facilitate blonanserin
release by promoting the formation of free volume of the PSA.
PSAs are viscoelastic materials that exhibit both solid- and
liquid-like behavior, which is dependent on the frequency of the
applied stress at a given temperature8. The viscoelastic nature of
PSA can be studied by rheological analyses, which does not
depend on surface properties of non-physiological substrates used
in adhesion performance tests but purely on the material proper-
ties9. In this study, rheological analyses were determined in terms
of “oscillation frequency sweep” to characterize the viscoelastic
properties of PSA. The parameters obtained were the complex
modulus (G*) consisting of the elastic modulus (G0) and theand shear-adhesion test results with different content of isopropyl






Figure 3 Oscillation frequency sweep data of DuroTaks 87-2287
containing 5% (w/w) blonanserin with no IPM (■) and with 4.0% (●),
8.0% (▲), 12.0% (▼) IPM, respectively. The elastic modulus G0 (A),
the viscous modulus G″ (B), and the damping factor tan δ (C) are
plotted versus the angular frequency (ω).
Figure 2 DSC curves of DuroTaks 87-2287 containing 5% (w/w)
blonanserin and different concentrations of isopropyl myristate (IPM).
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G ¼G0 Usin ωtð Þ þ G″Ucos ωtð Þ ð1Þ
where the elastic or storage modulus (G0) describes the solid-like
character and the viscous, or loss modulus (G″), describes the liquid-
like character of the PSA8. If G″4G0, the material is more liquid
than solid. The bonding of PSA occurs at low frequencies and the
PSA has to be more liquid-like since it must wet the substrate. The
debonding process occurs at high frequencies and requires a solid-
like behavior11. Therefore, at low frequencies G″ should be
predominate and at high frequencies G0 should be dominant. The
ratio of loss and storage moduli (G″/G0) is called loss tangent
(tan δ), which indicates the proportion of dissipated-to-stored
energy. Therefore, tan δ should be high at lower frequencies as a
reduction of G0 and should also be high at higher frequencies as an
increase in loss modulus20.
The moduli G0, G″ and loss tangent tan δ were plotted in
dependence of ω at T¼32 1C. The moduli G0 and G″ increased
with rising frequency at all IPM concentrations (Fig. 3). In Fig. 4
the moduli were plotted with increasing IPM concentrations for
frequencies of 0.1, 1, 10 and 100 rad/s. It shows that the
incorporation of increasing concentrations of IPM into the PSA
caused a decrease in the magnitude of G0 and G″. In the literature
the moduli of a polymer increases with increasing mechanical
strength and chain stiffness22. The decreased moduli indicated that
IPM incorporation caused a decrease in the mechanical strength
and resulted in a softer and more relaxed network of the PSA. The
reduction in the elastic modulus G0 also demonstrated the
plasticization effect of IPM on the PSA. The ﬂexibility of the
PSA was improved due to the plasticization of IPM by weakening
the cohesive interaction between polymer chains. Similar results
have been reported on the effect of ibuprofen incorporation into an
acrylic pressure-sensitive adhesive11.
The changes in Tg and rheological moduli with increasing
concentrations of IPM could explain the enhancement of the drug-
release rate. The lower values of Tg, G0 and G″, due to the
plasticization effect of IPM represented a less rigid and more
relaxed network of the PSA. The incorporation of IPM improved
the ﬂexibility of the PSA by increasing the intermolecular
separation of the polymer chains and expanded the free volume
in the PSA, which facilitated the release of blonanserin from the
patches. Hence the more IPM was included in the formulation thefaster drug release could be achieved. Wang et al.23 also reported
similar results of the effect of liquid parafﬁn on drug release from
patches based on a styrene–isoprene–styrene thermoplastic elasto-
mer copolymer.
PSA is a critical substance present in transdermal patches that is
responsible for physico-mechanical properties of the patch, drug
release, etc.9. Changes in the thermodynamic and rheological
properties of PSA after the addition of IPM can affect the adhesion
performance of the patches.
In the rolling ball tack test, the distance traveled by the ball on
the patch was measured as tack. Tack is the ability of an adhesive
to adhere quickly to another surface and a shorter stopping
distance means higher tack20. The data obtained is listed in
Figure 4 Elastic modulus G0 (A) and viscous modulus G″ (B) of DuroTaks 87-2287 containing 5% blonanserin (w/w) with increasing
concentrations of isopropyl myristate (IPM) at the angular frequency of 0.1, 1, 10 and 100 rad/s.
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decreased with increasing IPM concentration in the formulations.
This indicated that the tack of the patch increased with increasing
IPM concentration. Taking the results from DSC and rheological
tests into consideration, the effect of IPM on the tack of the patch
can be well explained. In the bonding process the lower moduli
value indicated increased ﬂexibility of the PSA, that is, the
incorporation of IPM made the PSA deform easily when in
contact with the substrate, allowing it to adhere more easily to
another substrate.
After application of a transdermal patch the PSA should remain
attached to the skin for a speciﬁc period of time despite tangential
stresses caused by both body movements and cloth friction20.
Shear-adhesion characterizes the resistance of a PSA to tangential
stresses, that is, the cohesion of the adhesive11. The shear-adhesion
test determined the time necessary to remove a standard area of the
patch from the plate under a standard load. In the test, the adhesive
failed cohesively, leaving some adhesive residue on the adherent
plate and some on the backing layer. The results are shown in
Table 1 and it was shown that the shear-adhesion decreased
signiﬁcantly with increasing concentrations of IPM. The time to
failure decreased from 12.66 to 0.53 h with increasing IPM
concentration from 0 to 12%. This result indicates that the
cohesive strength of the PSA was reduced by IPM incorporation.
The changes in the shear-adhesion of the patches coincided with
the effect of IPM on the mechanical properties of the PSA. On
addition of IPM, the PSA became softer and the entanglement in
the polymer was reduced. Hence the cohesive interactions between
the polymeric chains were weakened by the presence of IPM.
Taking these results together, the plasticization effect of IPM on
the PSA caused the enhancement of drug release, an increase in
the tack and a decrease in the shear-adhesion. Usually, most
formulation studies have focused on the maximum ﬂux of drug
through the skin. The ﬁndings above indicate that additives in
transdermal patches could change the adhesive properties of the
patch. If more transdermal systems are to be developed further
study of speciﬁc adhesive–drug-permeation enhancer systems is
essential.
4. Conclusions
In conclusion, the incorporation of IPM into the drug-in-adhesive
transdermal patch in which 5% blonanserin was dissolved inDURO-TAKs 87-2287 caused an enhancement of drug release,
an increase in the tack and a decrease in the shear-adhesion. This
phenomenon is attributed to the plasticization effect of IPM on the
PSA. The results indicated that the drug release and adhesion
performance of a transdermal patch are related to the mechanical
properties of the adhesive, which in turn would be affected by
addition of permeation enhancers. In addition, the effect of
permeation enhancers on drug release and mechanical properties
of the PSA should be taken into consideration in transdermal patch
formulation studies to ensure the proper viscoelastic properties of
the transdermal patch. There may be a trade-off between drug
release enhancement and adhesive properties of the transdermal
patch after the addition of permeation enhancers.References
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